within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01F_MacrolidesLincosamidesAndStreptogramins.J01FF01_Clindamycin;

model Clindamycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 3.1666666666666667e-06,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.0835,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0211,
    Tlag = 0,
    Vdp = 0.0342,
    k12 = 7.166666666666667e-06,
    k21 = 7.166666666666667e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Clindamycin</td></tr><tr><td>ATC code:</td><td>J01FF01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>83.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>11.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Clindamycin is a lincosamide antibiotic used for the treatment of a variety of serious bacterial infections, particularly those caused by susceptible anaerobic bacteria, streptococci, staphylococci, and pneumococci. It is approved and in current clinical use, commonly for skin infections, bone and joint infections, and as an alternative in patients allergic to penicillins.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single 300 mg oral dose of clindamycin.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=\"https://doi.org/10.1007/s40272-013-0017-5\">10.1007/s40272-013-0017-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23529866/\">https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Bouazza, N, et al., &amp; Tréluyer, JM (2012). Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. <i>British journal of clinical pharmacology</i> 74(6) 971–977. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2012.04292.x\">10.1111/j.1365-2125.2012.04292.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22486719/\">https://pubmed.ncbi.nlm.nih.gov/22486719</a></p></li><li><p>Armengol Álvarez, L, et al., &amp; Rozenski, J (2022). Ways to Improve Insights into Clindamycin Pharmacology and Pharmacokinetics Tailored to Practice. <i>Antibiotics (Basel, Switzerland)</i> 11(5) –. DOI:<a href=\"https://doi.org/10.3390/antibiotics11050701\">10.3390/antibiotics11050701</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35625345/\">https://pubmed.ncbi.nlm.nih.gov/35625345</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01FF01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Clindamycin;
